IRVINE, Calif., May 12, 2011 /PRNewswire/ -- Irvine Pharmaceutical Services is excited to announce the addition of Dr. Dorla Mirejovsky, as the Senior Director of Formulation Development. Dr. Mirejovsky brings with her over 25 years of experience in pharmaceutical development, drug delivery, and manufacturing of injectable drugs.
Dr. Mirejovsky most recently was responsible for the development and manufacture of several proprietary drug candidates at Spectrum Pharmaceuticals. While at Spectrum Pharmaceuticals, Dr. Mirejovsky authored CMC submissions for one NDA and several INDs. Prior to Spectrum, she spent nine years at Sicor Pharmaceuticals, Inc. developing numerous injectable products including Propofol Injectable Emulsion. Additionally, Dr. Mirejovsky has had similar roles at ISIS Pharmaceuticals, Inc. and Allergan, Inc.
Dr. Mirejovsky holds a Ph.D. in Physical Organic Chemistry from the University of Utrecht, Utrecht, The Netherlands preceded by a Diplome d'ingenieur d'ENSCP - Ecole Nationale Superieure de Chimie de Paris, Paris, France. She was a postdoctoral fellow at the Department of Chemistry, Northwestern University, Evanston, Illinois and at the Department of Chemistry, Duke University, Durham, North Carolina.
You can learn more about Irvine and the executive team at the upcoming 2011 AAPS National Biotech Conference in San Francisco, California, May 16-18, 2011. Visit us at our affiliate, Avrio Biopharma's booth 53!
About Irvine
Irvine Pharmaceutical Services, Inc. along with its affiliate, Avrio Biopharma, is a premier contract pharmaceutical manufacturing and development organization providing support to the pharmaceutical, biopharmaceutical, and medical device industries. Irvine and Avrio together provide full cGMP specialized pharmaceutical product development services such as, preformulation and formulation development, analytical method development, aseptic fill and finish, stability storage testing, and extractables and leachables testing. Learn more at www.irvinepharma.com or call 877-445-6554.
SOURCE Irvine Pharmaceutical Services, Inc.
